Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.
about
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphomaSmall-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapyActivation of DNA Damage Response Induced by the Kaposi's Sarcoma-Associated Herpes VirusCell Cycle Regulatory Functions of the KSHV Oncoprotein LANADisruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancerIdentification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agentsHsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteinsKaposi's sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic apparatus protein to regulate genome maintenance and segregation.Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis.Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.A human herpesvirus microRNA inhibits p21 expression and attenuates p21-mediated cell cycle arrestMDM2, MDMX and p53 in oncogenesis and cancer therapyA protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening.Kaposi's sarcoma herpesvirus upregulates Aurora A expression to promote p53 phosphorylation and ubiquitylationSurvivin is a therapeutic target in Merkel cell carcinoma.Contribution of viral mimics of cellular genes to KSHV infection and disease.Pegylated IFN-α sensitizes melanoma cells to chemotherapy and causes premature senescence in endothelial cells by IRF-1 mediated signalingPhosphorylation of the chromatin binding domain of KSHV LANAAltering the Anti-inflammatory Lipoxin Microenvironment: a New Insight into Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis.Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).Ribosomal protein S6 interacts with the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus.Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma.Mdm2 promotes systemic lupus erythematosus and lupus nephritisOncogenic Herpesvirus Utilizes Stress-Induced Cell Cycle Checkpoints for Efficient Lytic ReplicationNutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells.A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP.Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with multifunctional angiogenin to utilize its antiapoptotic functions.Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomasHuman Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.Regulation of the Abundance of Kaposi's Sarcoma-Associated Herpesvirus ORF50 Protein by Oncoprotein MDM2Kaposi's sarcoma-associated herpesvirus K-cyclin interacts with Cdk9 and stimulates Cdk9-mediated phosphorylation of p53 tumor suppressorMurine Gammaherpesvirus 68 LANA and SOX Homologs Counteract ATM-Driven p53 Activity during Lytic Viral ReplicationmTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disordersRole of Kaposi's sarcoma-associated herpesvirus C-terminal LANA chromosome binding in episome persistence.Targeting the MDM2-p53 interaction for cancer therapyThe latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.Kaposi's Sarcoma-Associated Herpesvirus MicroRNAs Target GADD45B To Protect Infected Cells from Cell Cycle Arrest and Apoptosis
P2860
Q21135231-F1C81110-5D36-40A9-A9BB-B21B60EAE987Q24651380-5A8ECE27-C456-4FF9-B4A1-61AF55BDD858Q26743368-BB9EAFC0-9C31-4FED-B9E8-36787D614E73Q26749612-AF8FA041-C261-48D3-8158-F809B15D4650Q27020978-1104E89D-46C8-4869-8146-363D6F7B2574Q27318801-E5715B27-BAD5-4E93-8688-67EC3FD7DF3DQ28485399-2E25FA6A-291F-4A89-AD4F-6E87F818F795Q30482603-7001A165-D756-453B-B42B-12E1205341E4Q33301012-85015ABC-672C-4EB6-A3F1-DA5AE2689289Q33545232-9B79EE7D-EC39-4CC0-9DCE-6DAEAF7FF7EBQ33826818-2FE04ACC-D750-4436-8992-B9884AAFCCFBQ34166049-3EE41880-E2B8-48B4-A064-EF229E91D39DQ34179693-E9FC39F3-7168-4EAF-ACCB-8AC5C60D8B7AQ34186981-940B3242-7185-4178-AD08-E5A8EEF9F202Q34273814-AEDDADDF-33EF-4C9B-9409-7111266AA20BQ34303583-186111DF-CD47-4D8B-A231-A97C9228076DQ34443056-63D32CEB-B173-45A7-9AF1-59C19A176224Q34456086-0C96CBFD-7644-4327-BDF5-741F766585A5Q34541350-9060BDF4-70D5-4CE2-8435-B331A5ECDEDBQ34982229-5750B059-0ACF-40FA-B892-C680ACAC9D5EQ35192690-01EFE425-9B2C-4486-AAC9-B71DDA07AE39Q35235757-F078B306-AB7E-4C23-A317-08EE4731FB78Q35758450-B1658265-485D-450D-AEFC-90D14D746D51Q35927487-E8624738-2231-4AC9-9634-3A55A117274AQ35954902-95EDC526-656D-40C8-9B40-5E1AA6D5E8ADQ35973676-C7DBF2AF-B2E1-4A25-AFB1-7C751C9F69BDQ36023151-F35079C4-7EF1-4A5C-B962-BD52BC66C716Q36048192-CBCE3ADD-F274-4B10-96AA-A2C8B6645994Q36106299-46E6F51D-A05B-47F9-899B-F0CB42739558Q36152200-E3A28551-9F5F-4582-AA2A-8F0C87A231F3Q36423989-FBD16120-B135-4EB3-9643-11799F61FD2BQ36736774-3CDBEF39-0CA6-433F-8105-2DA632104B4EQ36745445-3050E1E5-542D-4E38-A184-5EE1CA305EADQ36890993-A7249CD0-57C5-4EE6-BA13-D1A70FF1242DQ37016504-5F958E85-CFA7-434F-90FB-36551A26DD48Q37157253-AF03131B-FCBF-4775-BBF5-861697C835BCQ37177586-8FE5541B-AFBC-4F4D-87A7-1F8B1A5E9639Q37380228-BA53363A-6E2F-4816-8DE7-65D5F0815870Q37477829-5C43DE20-633F-46B5-8526-BBABF67918B0Q37593234-CF78DD6F-9270-4D4F-937E-FCFB065344AF
P2860
Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.
@ast
Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.
@en
type
label
Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.
@ast
Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.
@en
prefLabel
Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.
@ast
Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.
@en
P2093
P2860
P356
P1476
Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas
@en
P2093
Grzegorz Sarek
Guergana Iotzova
Juergen Haas
Juulia Enbäck
Marikki Laiho
Sari Kurki
P2860
P304
P356
10.1172/JCI30945
P407
P577
2007-03-15T00:00:00Z